Maynard Um
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) Tops Q1 EPS by 217c
-
-
-
-
-
-
-
Mizuho on Sarepta Therapeutics (SRPT): data de-risks siRNA platform, supports BIC potential
-
-
-
-
-
-
-
Sarepta plans regulatory submissions for two Duchenne drugs by April 2026
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) PT Lowered to $29 at Wedbush
-
-
-
-
-
-
-
Sarepta reports positive three-year results for Duchenne gene therapy
-
-
-
-
-
-
-
Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty
-
-
-
-
-
-
-
Sarepta advances SRP-1003 trial, triggers $200 million milestone payment
-
422,864 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

